Compare RLX Technology Inc (RLX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? RLX Technology Inc trades at $1.7 (market cap $2.09B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.3× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.85% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold RLX Technology Inc for 36 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RLX | TVTX | |
|---|---|---|
Market Cap | $2.09B | $4.88B |
Volume | 969,724 | 1,668,577 |
Sector | Consumer Staples | Health |
52-Week High | $2.57 | $67.52 |
52-Week Low | $1.68 | $26.79 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $817.70M | $5.01B |
Dividend Yield | 5.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX Technology trades at $1.71, down 0.58% with bearish technical signals. The stock recently hit 52-week lows despite solid fundamentals including $3.62B revenue and 21.87% net margin. Recent earnings missed expectations but international expansion shows growth potential. Technical indicators show selling pressure with bearish moving averages.
RLX presents a value opportunity with discounted valuation (P/E 15.34, P/B 0.9) but faces execution risks. The bearish technical trend and earnings misses offset strong cash flow and international growth. Investors should weigh the discounted valuation against recent price weakness and margin compression concerns.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
